AU Patent

AU2018354972B2 — An improved process for the preparation of ribociclib and its salts

Assigned to Fresenius Kabi Oncology Ltd · Expires 2021-07-08 · 5y expired

What this patent protects

The invention relates to a process for the preparation of ribociclib of formula V or its salts. The invention provides novel crystalline forms of ribociclib succinate and ribociclib trifluoroacetate. The present invention also relates to pharmaceutical compositions comprising a c…

USPTO Abstract

The invention relates to a process for the preparation of ribociclib of formula V or its salts. The invention provides novel crystalline forms of ribociclib succinate and ribociclib trifluoroacetate. The present invention also relates to pharmaceutical compositions comprising a crystalline form of ribociclib succinate and at least a pharmaceutically acceptable carrier. It further relates to the use of such compositions in the treatment of cancer.

Drugs covered by this patent

Patent Metadata

Patent number
AU2018354972B2
Jurisdiction
AU
Classification
—
Expires
2021-07-08
Drug substance claim
No
Drug product claim
No
Assignee
Fresenius Kabi Oncology Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.